Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f)
Status:
Recruiting
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Determine the
Safety and Immunogenicity of an Adenoviral-Vector Based Respiratory Syncytial Virus (RSV) F
Protein Vaccine (VXA-RSV-f) Expressing Protein F and dsRNA Adjuvant Administered Orally to
Healthy Volunteers